Bromperidol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Bromperidol
Accession Number
DB12401
Type
Small Molecule
Groups
Approved, Investigational
Description

Bromperidol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders, among others.

Structure
Thumb
Synonyms
Not Available
External IDs
R 11,333 / R-11333
Categories
UNII
LYH6F7I22E
CAS number
10457-90-6
Weight
Average: 420.322
Monoisotopic: 419.08962
Chemical Formula
C21H23BrFNO2
InChI Key
RKLNONIVDFXQRX-UHFFFAOYSA-N
InChI
InChI=1S/C21H23BrFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
IUPAC Name
4-[4-(4-bromophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
SMILES
OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Br)C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2,5-Dimethoxy-4-ethylamphetamineBromperidol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamineBromperidol may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.
3,4-MethylenedioxyamphetamineBromperidol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
4-Bromo-2,5-dimethoxyamphetamineBromperidol may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Bromperidol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Bromperidol.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Bromperidol.
AcetaminophenThe serum concentration of Bromperidol can be increased when it is combined with Acetaminophen.
AcetazolamideThe risk or severity of adverse effects can be increased when Bromperidol is combined with Acetazolamide.
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Bromperidol.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
2448
PubChem Substance
347828647
ChemSpider
2354
BindingDB
81484
ChEBI
31305
ChEMBL
CHEMBL28218
Wikipedia
Bromperidol
ATC Codes
N05AD06 — Bromperidol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
4CompletedTreatmentSchizoaffective Disorders / Schizophrenia and Disorders With Psychotic Features / Schizophrenic Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00723 mg/mLALOGPS
logP3.78ALOGPS
logP3.83ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)13.97ChemAxon
pKa (Strongest Basic)8.07ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area40.54 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity105.41 m3·mol-1ChemAxon
Polarizability41.37 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00xr-3900100000-ff9736b6f93bc161b31c

Taxonomy

Description
This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Alkyl-phenylketones
Alternative Parents
Phenylpiperidines / Phenylbutylamines / Butyrophenones / Aryl alkyl ketones / Benzoyl derivatives / Aralkylamines / Fluorobenzenes / Bromobenzenes / Aryl bromides / Aryl fluorides
show 9 more
Substituents
Alkyl-phenylketone / Phenylpiperidine / Butyrophenone / Phenylbutylamine / Benzoyl / Aryl alkyl ketone / Bromobenzene / Fluorobenzene / Halobenzene / Aralkylamine
show 23 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 16:14 / Updated on October 01, 2018 15:14